The Abbreviated Methacholine Challenge Test is Safe for Children.

Area of Science:

• Pediatric Pulmonology
• Respiratory Medicine
• Clinical Trials

Background:

• The methacholine challenge test (MCT) is a standard diagnostic tool for asthma.
• Traditional MCT protocols can be lengthy, potentially causing patient discomfort and logistical challenges.
• Evaluating shorter, safer protocols is crucial for improving pediatric respiratory diagnostics.

Purpose of the Study:

• To assess the safety and efficacy of an abbreviated methacholine challenge test (MCT) protocol in pediatric patients.
• To determine if a modified, shorter MCT protocol yields comparable safety outcomes to the standard protocol.
• To quantify the time savings associated with the abbreviated MCT.

Main Methods:

• A prospective, observational study involving 112 children aged 6-18 years undergoing MCT.
• Implementation of an abbreviated protocol with dose escalation adjustments based on forced expiratory volume at 1-second (FEV1) decline.
• Safety monitoring included adverse events, FEV1 decline >40%, hypoxemia, and cough; test duration and doses were recorded.

Main Results:

• The abbreviated MCT protocol was safely completed by all 112 participants.
• No significant clinical adverse events were observed; exaggerated responses occurred in 2.7% of participants, consistent with full-length protocols.
• The abbreviated protocol resulted in significant time savings, reducing overall test duration by an average of 14-22 minutes depending on test outcome.

Conclusions:

• The abbreviated methacholine challenge test (MCT) protocol is a safe and effective alternative for pediatric asthma diagnosis.
• This shortened protocol offers substantial time savings, enhancing patient experience and clinical efficiency.
• The findings support the adoption of this abbreviated MCT in pediatric respiratory assessments.